GRETCHEN FULKERSON: Open Payments
NPI 1720356256 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 35 payments from 13 companies in 2025. Trend: 2023 $52 · 2024 $516 · 2025 $731
Food & beverage: $731
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $245 |
| Collegium Pharmaceutical, Inc. | 6 | $109 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $81 |
| Novo Nordisk Inc | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Abbott Laboratories | 1 | $35 |
| Globus Medical, Inc. | 1 | $33 |
| Merck Sharp & Dohme LLC | 2 | $28 |
| Lilly USA, LLC | 1 | $21 |
Products named: VRAYLAR, Jornay PM, Kerendia, CAPLYTA, SHINGRIX, AFINION 2, Senza, LO LOESTRIN FE.
Industry payments across TX — which companies pay providers there.
